The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether fibre‐enriched enteral nutrition changes all‐cause mortality compared with control (very low certainty).
It is very uncertain whether fibre‐enriched enteral nutrition changes systemic inflammatory response syndrome compared with control (very low certainty).
Immunonutrition showed no clear difference in systemic inflammatory response syndrome compared with control (low certainty).
It is very uncertain whether fibre‐enriched enteral nutrition changes organ failure compared with control (very low certainty).
The review found no eligible studies for this question.
Enteral nutrition may leads to lower all‐cause mortality compared with no intervention (low certainty).
It is very uncertain whether enteral nutrition changes systemic inflammatory response syndrome compared with no intervention (very low certainty).
It is very uncertain whether enteral nutrition changes organ failure compared with no intervention (very low certainty).
It is very uncertain whether enteral nutrition changes adverse events compared with no intervention (very low certainty).
Immunonutrition showed no clear difference in organ failure compared with control (low certainty).
It is very uncertain whether immunonutrition changes adverse events compared with control (very low certainty).
It is very uncertain whether probiotics changes all‐cause mortality compared with control (very low certainty).
It is very uncertain whether probiotics changes systemic inflammatory response syndrome compared with control (very low certainty).
It is very uncertain whether probiotics changes organ failure compared with control (very low certainty).
Probiotics showed no clear difference in adverse events compared with control (low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with control (very low certainty).
Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).